Related Experiment Video
Updated: May 6, 2026

Noninvasive Assessment of Cardiac Abnormalities in Experimental Autoimmune Myocarditis by Magnetic Resonance Microscopy Imaging in the Mouse
Published on: June 20, 2014
Immune Checkpoint Inhibitor-Related Myocarditis: A Single Center Observational Registry.
Grace Alexander1, Ibrahim Mortada1, Mohammed Mhanna2
1Department of Medicine, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA.
Immune checkpoint inhibitor (ICI) myocarditis is rare but serious. Patients with pre-existing cardiovascular disease face higher risks, underscoring the need for vigilant cardiac monitoring during ICI therapy.
Area of Science:
- Cardiology
- Oncology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) can cause myocarditis, a rare condition with significant mortality.
- Understanding ICI-related myocarditis is crucial for managing cancer patients undergoing immunotherapy.
Purpose of the Study:
- To describe patient characteristics, treatment, and outcomes of ICI-related myocarditis.
- To identify risk factors and clinical insights for ICI-induced myocarditis.
Main Methods:
- Single-center observational registry of ICI-related myocarditis cases (2009-2024).
- Retrospective data collection from electronic medical records.
- Statistical analysis including t-tests, Wilcoxon rank-sum test, and Fisher's exact test.
Main Results:
- Eighteen patients with ICI-related myocarditis were identified.
- Patients with ICI myocarditis had higher rates of coronary artery disease and obstructive sleep apnea.
- A significant proportion experienced major adverse cardiac events (MACE), myasthenia gravis-like overlap syndrome, or myositis/rhabdomyolysis.
Conclusions:
- ICI-related myocarditis has a low incidence (0.48%) but a high rate of MACE.
- Pre-existing cardiovascular disease increases the risk of developing ICI-related myocarditis.
- Close cardiovascular monitoring is essential for patients receiving ICI therapy.
More Related Videos
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
Related Concept Videos
Myocarditis I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Pericarditis III: Medical Management
Cardiomyopathy IV: Restrictive Cardiomyopathy